Skip to main content

Procedural Sedation

2
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Paion
PaionGermany - Aachen
2 programs
1
1
CNS 7056Phase 21 trial
RemimazolamPhase 11 trial
Active Trials
NCT03329014Completed12Est. Jun 2017
NCT00869440Completed100Est. Sep 2009
Eisai
EisaiChina - Liaoning
2 programs
AQUAVAN®PHASE_2_31 trial
Fospropofol disodiumPHASE_41 trial
Active Trials
NCT00327392Completed123Est. Dec 2007
NCT01195103Terminated13Est. Mar 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EisaiFospropofol disodium
EisaiAQUAVAN®
PaionCNS 7056
PaionRemimazolam

Clinical Trials (4)

Total enrollment: 248 patients across 4 trials

NCT01195103EisaiFospropofol disodium

Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery

Start: Feb 2011Est. completion: Mar 201113 patients
Phase 4Terminated

A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures.

Start: May 2006Est. completion: Dec 2007123 patients
Phase 2/3Completed

Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy

Start: Mar 2009Est. completion: Sep 2009100 patients
Phase 2Completed
NCT03329014PaionRemimazolam

A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability

Start: May 2017Est. completion: Jun 201712 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.